Scleroderma

From Pathogenesis to Comprehensive Management
2012
ISBN: 978-1-4419-5773-3
Verlag: Springer

Buch, Englisch, 689 Seiten, Book, Gewicht: 2093 g

This essential resource presents the most up-to-date information on scleroderma. A clear and concise synthesis of current concepts in pathogenesis and modern approaches to management, this book is comprised of the authoritative work of international experts. With an integrated multidisciplinary approach to comprehensive care, this book is easily accessible for health care professionals in many fields. It is a valuable resource for rheumatologists, pulmonologists, cardiologists, gastroenterologists, nephrologists and all those involved in the care of scleroderma patients.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Varga, John

Denton, Christopher P.

Wigley, Fredrick M.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Kardiologie, Angiologie, Phlebologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Nephrologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Pneumologie, Atmung, Asthma
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Rheumatologie, Muskelerkrankungen
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gastroentereologie, Proktologie

Inhaltsverzeichnis

Foreword       Stephen Katz MD, PhD, Director, NIAMS
Foreword       A personal view: Luke Evnin, PhD, President, SRF
 
Preface           John Varga, MD, Christopher P. Denton, PhD, FRCP, Fredrick M. Wigley, MD 
Section I. IntroductionChapter 1 – Historical Perspective – Christopher P. Denton, PhD, FRCP, and Carol Black
Chapter 2 - Therapeutic evolution: a professor’s view – Frank A. Wollheim, MD, PhD, FRCP                  
 
Section II: Epidemiology, Genetics and Classification
Chapter 3 – Overview: Epidemiology, Genetics and Classification – Christopher P. Denton, PhD, FRCP
Chapter 4 – Epidemiology and Environmental Risk Factors – Jammie K. Barnes, MD,
and Maureen D. Mayes, MD, MPH
Chapter 5  – Genetic Factors – Yannick Allanore, MD, PhD, and Filemon K. Tan, MD, PhD
Chapter 6 – Disease Subsets in Clinical Practice  – Robyn Therese Domsic, MD, MPH,
and Thomas A. Medsger, Jr., MD
Chapter 7 – Evolving Concepts of Diagnosis and Classification – Lorinda Chung, MD, MS, Jaap Fransen, MD, and Frank H.J. Van den Hoogen, MD, PhD
Chapter 8 – Disease Classification using Molecular Signatures  – Michael L. Whitfield, PhD, and Robert Lafyatis, MD
 
Section III: Scleroderma in Children
Chapter 9 – Juvenile Localized Scleroderma – Francesco Zulian, MD
Chapter 10 - Juvenile Systemic Scleroderma - Ivan Foeldvari, MD
 
Section IV:  Other Fibrosing Skin Conditions
Chapter 11 – Scleroderma Mimics –Laura K. Hummers, MD, ScM
Chapter 12 - Localized Forms of Scleroderma in Adults – Amy E. Gilliam, MD, and Anita C. Gilliam, MD, PhD
Chapter 13 - Nephrogenic Systemic Fibrosis – Peter J. Wermuth, PhD, and Sergio A. Jimenez, MD
 
Section V: Pathogenetic Basis
Chapter 14 - Overview: Integrated Pathogenesis – John Varga, MD
Chapter 15 - Immunological Mechanisms – Francisco Boin, MD, and Carlo Chizzolini, MD
Chapter 16 - Innate Immunity – Keith B. Elkon, MD, and Julia J. Rhiannon, MD, MSW
Chapter 17 – Autoantibodies in Pathogenesis – Kimberly Doering, BS, and Antony Rosen, MB ChB, BSc (Hons)
 
Chapter 18 - The Clinical Aspects of Autoantibodies - John D. Pauling, BMBS, MRCP, and Neil McHugh, MB, ChB, MD, FRCP, FRCPath
 
Chapter 19 – Mechanisms of Vascular Disease – Bashar Kalaheh, MD, and Mary Jo Mulligan-Kehoe, PhD
 
Chapter 20  - Vascular Biomarkers – Laura K. Hummers, MD, ScM 
Chapter 21 – Mechanisms of Fibrosis – John Varga, MD
 
Chapter 22 – Fibrosis: Insights from the stiff skin syndrome – Elizabeth E. Gerber, BS, and Harry C. Dietz, MD
 
Chapter 23 - Biomarkers of Fibrosis – Christian Beyer, MD, Oliver Distler, MD, and Jörg H.W. Distler, MD
 
Chapter 24 – Overview of Animal Models – Christopher P. Denton, PhD, FRCP, and Robert Lafyatis, MD
 
Section VI: Cardiovascular Manifestations and Management
Chapter 25 – Overview: Cardiovascular Manifestations and Management – Fredrick M. Wigley, MD
Chapter 26 – Raynaud Phenomenon  – Arianne Herrick and Fredrick M. Wigley, MD
Chapter 27 – Nailfold Capillaroscopy – Maurizio Cutolo, MD and Vanessa Smith, MD, PhD28SystemicVascular Disease, MD, PhD, MD, FRCPChapter 29 – Scleroderma Renal Crisis – Christopher P. Denton, PhD, FRCP, and Virginia Steen, MD
Chapter 30 – Cardiac Involvement –Sanjiv J. Shah, MD, and André Kahan, MD, PhD
Chapter 31 – Erectile Dysfunction – Edward V. Lally, MD, Arthur L. Burnett, MD, MBA, FACS, and Trinity J. Bivalacqua, MD, PhD
 
Section VII: Pulmonary manifestations and management
Chapter 32 – Overview: Pulmonary manifestations and management – Christopher P. Denton, PhD, FRCP
Chapter 33 – Clinical Assessment of Lung Disease – Greg J. Keir, MBBS, FRACP, Richard M. Silver, MD, and Athol U. Wells, MD, FRCP
Chapter 34 – Computerized Tomography of Interstitial Lung Disease – Athol U. Wells, MD, FRCP, and Jonathan Goldin MD, PhD, FRCR
Chapter 35 – Treatment of interstitial lung disease – Dinesh Khanna, MD, MS, and Donald P. Tashkin, MD
Chapter 36 – Clinical Assessment of Pulmonary Hypertension – Harrison W. Farber, MD, Michael York,